Charles J Yeo Selected Research

Adenocarcinoma

4/2022	HuR Plays a Role in Double-Strand Break Repair in Pancreatic Cancer Cells and Regulates Functional BRCA1-Associated-Ring-Domain-1(BARD1) Isoforms.
1/2022	A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer.
1/2022	Intraoperative Cytologic Sampling for Resected Pancreatic and Periampullary Adenocarcinoma with Implications for Locoregional Recurrence-Free Survival.
1/2022	The RNA-Binding Protein HuR Posttranscriptionally Regulates the Protumorigenic Activator YAP1 in Pancreatic Ductal Adenocarcinoma.
11/2021	The Impact of Neoadjuvant Treatment on Survival in Patients Undergoing Pancreatoduodenectomy With Concomitant Portomesenteric Venous Resection: An International Multicenter Analysis.
3/2021	Margin-Positive Pancreatic Ductal Adenocarcinoma during Pancreaticoduodenectomy: Additional Resection Does Not Improve Survival.
1/2021	Combined Targeting of PARG and Wee1 Causes Decreased Cell Survival and DNA Damage in an S-Phase-Dependent Manner.
1/2021	Sequencing of an Undifferentiated Carcinoma with Osteoclast-Like Giant Cells of the Pancreas: A Case Report.
1/2021	AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with PARG Inhibition.
12/2020	ASO Author Reflections: Margin-Positive Pancreatic Ductal Adenocarcinoma During Pancreaticoduodenectomy: Additional Resection Does Not Improve Survival.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Charles J Yeo Research Topics

Disease

120	Neoplasms (Cancer) 01/2022 - 01/2002
110	Adenocarcinoma 04/2022 - 01/2002
87	Pancreatic Neoplasms (Pancreatic Cancer) 04/2022 - 01/2002
16	Pancreatic Fistula (Pancreatic Fistulas) 01/2022 - 11/2004
16	Neoplasm Metastasis (Metastasis) 04/2015 - 01/2002
14	Carcinoma (Carcinomatosis) 01/2021 - 01/2002
10	Chronic Pancreatitis 01/2018 - 01/2002
9	Neoplasms, Cystic, Mucinous, and Serous 01/2020 - 01/2002
7	Pancreatitis 09/2022 - 03/2002
7	Carcinogenesis 01/2022 - 03/2003
6	Wounds and Injuries (Trauma) 12/2021 - 06/2002
5	Inflammation (Inflammations) 04/2015 - 12/2004
4	Diabetes Mellitus 11/2021 - 12/2004
4	Obesity 01/2021 - 02/2009
4	Breast Neoplasms (Breast Cancer) 04/2013 - 01/2003
4	Fistula 01/2013 - 12/2004
3	Acinar Cell Carcinoma 01/2016 - 03/2002
3	Hemorrhage 01/2014 - 02/2003
3	Disease Progression 09/2008 - 12/2004
3	Abscess 11/2006 - 02/2003
3	Adenoma (Adenomas) 01/2005 - 01/2002
3	Pancreatic Diseases (Pancreatic Disease) 01/2003 - 03/2002
2	Margins of Excision 03/2021 - 01/2018
2	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 01/2005
2	Pathologic Constriction (Stenosis) 01/2020 - 05/2006
2	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2020 - 03/2003
2	Esophageal Neoplasms (Esophageal Cancer) 01/2020 - 04/2015
2	Obstructive Jaundice (Cholestatic Jaundice) 01/2018 - 10/2008
2	Tuberculosis (Tuberculoses) 01/2018 - 02/2005
2	Pneumonia (Pneumonitis) 01/2017 - 01/2015
2	Insulinoma 01/2017 - 05/2006
2	Pain (Aches) 04/2015 - 04/2012

Drug/Important Bio-Agent (IBA)

37	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2002
18	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 01/2002
14	Messenger RNA (mRNA)IBA 01/2022 - 03/2004
11	Gemcitabine FDA Link 01/2018 - 04/2006
9	OsteopontinIBA 04/2015 - 03/2004
8	Biomarkers (Surrogate Marker)IBA 01/2021 - 03/2002
7	EnzymesIBA 01/2021 - 05/2009
6	AntigensIBA 04/2022 - 01/2003
6	Pharmaceutical PreparationsIBA 11/2021 - 12/2006
6	Fluorouracil (Carac)FDA LinkGeneric 01/2021 - 07/2008
6	MesothelinIBA 03/2015 - 09/2003
6	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2010 - 07/2003
6	Tumor Biomarkers (Tumor Markers)IBA 09/2004 - 04/2002
5	Protein Isoforms (Isoforms)IBA 04/2022 - 10/2010
5	RNA-Binding Proteins (RNA-Binding Protein)IBA 01/2022 - 09/2008
5	Antineoplastic Agents (Antineoplastics)IBA 01/2019 - 05/2007
5	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 08/2011 - 01/2002
5	Nicotine FDA Link 01/2011 - 07/2009
5	Biological ProductsIBA 12/2006 - 11/2002
5	fascinIBA 02/2006 - 07/2002
4	Phosphotransferases (Kinase)IBA 01/2021 - 10/2003
4	MucinsIBA 04/2012 - 01/2002
4	Angiotensin IIIBA 08/2011 - 05/2007
4	RNA (Ribonucleic Acid)IBA 02/2009 - 05/2002
4	Complementary DNA (cDNA)IBA 11/2004 - 04/2002
3	Amylases FDA Link 06/2018 - 05/2007
3	Mitomycin (Mitomycin-C)FDA LinkGeneric 01/2018 - 05/2003
3	Cadherins (E-Cadherin)IBA 01/2017 - 09/2010
3	Colloids (Colloid)IBA 04/2016 - 01/2002
3	AntibodiesIBA 03/2015 - 02/2006
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2014 - 08/2009
3	ParaffinIBA 07/2012 - 05/2002
3	Formaldehyde (Formol)FDA Link 07/2012 - 05/2002
3	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 01/2011 - 12/2009
3	SmokeIBA 10/2010 - 07/2009
3	Deoxycytidine KinaseIBA 09/2010 - 04/2006
3	OligonucleotidesIBA 04/2004 - 12/2003
3	beta CateninIBA 09/2003 - 03/2002
2	AlbuminsIBA 09/2022 - 01/2021
2	Cancer VaccinesIBA 01/2022 - 02/2011
2	Thymidylate SynthaseIBA 01/2021 - 07/2008
2	poly ADP-ribose glycohydrolaseIBA 01/2021 - 01/2019
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2020 - 02/2014
2	ElementsIBA 01/2020 - 02/2014
2	Peptide Hydrolases (Proteases)FDA Link 01/2018 - 08/2013
2	TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA 01/2016 - 08/2012
2	thymoquinoneIBA 01/2016 - 08/2009
2	Diphtheria ToxinIBA 03/2015 - 10/2008
2	Trastuzumab (Herceptin)FDA Link 01/2015 - 01/2005

Therapy/Procedure

48	Pancreaticoduodenectomy 09/2022 - 09/2002
41	Therapeutics 01/2022 - 11/2002
20	Pancreatectomy 01/2022 - 03/2002
14	Drug Therapy (Chemotherapy) 01/2022 - 02/2005
9	Length of Stay 09/2022 - 02/2003
6	Lymph Node Excision (Lymph Node Dissection) 09/2014 - 09/2002
5	Neoadjuvant Therapy 11/2021 - 08/2009
4	Operative Time 01/2020 - 12/2004
4	Esophagectomy 01/2020 - 02/2003
3	Cholecystectomy 01/2020 - 09/2002
3	Stents 01/2020 - 05/2005
3	Radiotherapy 01/2019 - 10/2005
3	Splenectomy 01/2018 - 08/2013
3	Laparotomy 01/2016 - 01/2002
3	Laparoscopic Cholecystectomy 06/2007 - 06/2002
3	Gastrectomy 12/2005 - 09/2002
2	Immunotherapy 01/2022 - 02/2011
2	Adjuvant Chemotherapy 11/2021 - 01/2018
2	Pancreaticojejunostomy 01/2017 - 05/2009